Registration Number
0221U106470,
0121U107508
, R & D reports
Title
620. Personalization of the treatment and development of new biologically active substances in optimization of pharmacotherapy of a few socially important diseases
popup.stage_title
Head
Antonenko Petro В., д.мед.н.
Registration Date
07-12-2021
Organization
Odessa National Medical University
popup.description2
Among the patients with pulmonary tuberculosis (TB), the “intermediate metabolizers” according to CYP3A4 *1B genotype was more often observed than among healthy volunteers. In individuals with “slow metabolizers” genotype of CYP3A4*1B the treatment outcome was quite better, than in “rapid metabolizers”. Thus in “slow metabolizers” according to CYP3A4*1B and CYP3A4*1G genotype the initial hepatic function was better than in other patients. completion of in-patient stage of anti-TB treatment the level of cytolysis and toxicity indexes was much higher than in fast metabolizers. That is why detection of CYP3A4*1G genotype of TB patients at the beginning of TB treatment could help to recognize a group of the individuals with increased risk of liver injury during therapy. That is why the “slow metabolizers” genotype is a prognostic sign of putative hepatotoxicity during anti-tuberculosis therapy.
Current research are fulfilled according to planning task of Ministry of Health of Ukraine
Product Description
popup.authors
Antonenko Kateryna O.
Antonenko Petro B.
Helmboldt Volodymyr О.
Kovalchuk Iryna
Kresyun Valentyn Yo.
Lytvynchuk Iryna V.
Lobashova Katerynа H.
Poludenko Hanna O.
Prystupa Bohdan V.
Razkevych Olesia S.
Rozhkovsky Yaroslav V.
Shemonayeva Katerynа F.
Shyshkin Ivan O.
Yunusova Saida I.
popup.nrat_date
2021-12-07
